Diametric Capital’s Carisma Therapeutics CARM Stock Holding History

Diametric Capital’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,027	Closed	-$17K	–	266
2022 Q2	$17K	Buy	+1,027	New	+$11.8K	0.01%	265

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Diametric Capital's CARM Position: Q3 2022 in Review

Diametric Capital sold out of Carisma Therapeutics (CARM) in Q3 2022, closing a stake of 1,027 shares — an estimated $17K sold.

Diametric Capital first reported a position in CARM in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 68 funds tracked by Wall St. Rank hold CARM as of Q3 2022.

Diametric Capital reported no remaining Carisma Therapeutics position as of Q3 2022 after selling out during the quarter.
Diametric Capital sold 1,027 Carisma Therapeutics shares in Q3 2022, an estimated $17K.
Diametric Capital first reported a position in Carisma Therapeutics in Q2 2022 and held it in 1 quarter.
Diametric Capital's Carisma Therapeutics position peaked at $17K in Q2 2022.
68 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2022.

Based on Diametric Capital's 13F filing for Q3 2022, filed 14 Nov 2022.